-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alkermes Plc (NASDAQ:ALKS) Shares Purchased by Eagle Asset Management Inc.
Alkermes Plc (NASDAQ:ALKS) Shares Purchased by Eagle Asset Management Inc.
Eagle Asset Management Inc. lifted its holdings in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 13.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 855,540 shares of the company's stock after acquiring an additional 102,490 shares during the period. Eagle Asset Management Inc.'s holdings in Alkermes were worth $19,104,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in ALKS. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Alkermes during the first quarter worth $56,494,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Alkermes during the second quarter worth $37,882,000. Victory Capital Management Inc. boosted its holdings in shares of Alkermes by 1,265.8% during the second quarter. Victory Capital Management Inc. now owns 1,175,574 shares of the company's stock worth $35,020,000 after purchasing an additional 1,089,504 shares during the last quarter. Emerald Advisers LLC acquired a new stake in shares of Alkermes during the second quarter worth $31,026,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Alkermes during the second quarter worth $27,688,000. Institutional investors and hedge funds own 96.15% of the company's stock.
Get Alkermes alerts:Alkermes Trading Up 0.2 %
NASDAQ:ALKS opened at $28.69 on Thursday. The business's 50-day moving average is $26.26 and its two-hundred day moving average is $24.96. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.24 and a quick ratio of 1.89. Alkermes plc has a 12 month low of $21.75 and a 12 month high of $32.79. The firm has a market capitalization of $4.71 billion, a PE ratio of -36.78 and a beta of 0.57.
Alkermes (NASDAQ:ALKS – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Alkermes had a negative net margin of 11.41% and a negative return on equity of 1.10%. The company had revenue of $252.36 million during the quarter, compared to analysts' expectations of $271.45 million. During the same period last year, the business earned ($0.02) earnings per share. The company's revenue for the quarter was down 14.2% compared to the same quarter last year. Research analysts predict that Alkermes plc will post -0.29 earnings per share for the current fiscal year.Wall Street Analyst Weigh In
ALKS has been the topic of several analyst reports. Bank of America raised their price objective on Alkermes from $27.00 to $28.00 in a report on Sunday, January 8th. Piper Sandler raised Alkermes from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $26.00 to $30.00 in a research report on Thursday, November 3rd. StockNews.com lowered Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 2nd. JPMorgan Chase & Co. cut their target price on Alkermes from $33.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, December 6th. Finally, Mizuho increased their target price on Alkermes from $34.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, November 22nd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.89.
About Alkermes
(Get Rating)
Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
Recommended Stories
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- T-Mobile Delivers Where it Matters Most to Investors
- Exxon Mobil Could Gush To New Highs Very Soon
- Costco Continues to be the Right Stock for the Right Time
- Peloton May Reward Traders, Requires Long-Term Discipline
- Bed Bath & Beyond Is Circling the Drain
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Get Rating).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
據Holdings Channel.com報道,鷹資產管理公司在第三季度增持了艾爾建股份有限公司(納斯達克代碼:ALKS-GET Rating)13.6%的股票。在此期間,該公司增持了102,490股,持有該公司855,540股股票。截至最近一個季度末,Eagle Asset Management Inc.持有的Alkermes股份價值19,104,000美元。
其他幾家對沖基金也對它們在ALKS的頭寸進行了調整。ArrowStreet Capital Limited Partnership在第一季度收購了Alkermes價值56,494,000美元的新股份。安大略省養老金計劃信託基金的醫療保健在第二季度收購了Alkermes價值37,882,000美元的新股。勝利資本管理公司在第二季度增持了1,265.8%的Alkermes股票。勝利資本管理公司現在擁有1,175,574股該公司股票,價值35,020,000美元,在上個季度又購買了1,089,504股。Emerald Advisers LLC在第二季度收購了Alkermes價值31,026,000美元的新股。最後,Emerald Mutual Fund Advisers Trust在第二季度收購了Alkermes價值27,688,000美元的新股份。機構投資者和對沖基金持有該公司96.15%的股票。
到達阿爾克梅斯警報:Alkermes交易上漲0.2%
納斯達克:ALKS週四開盤報28.69美元。該業務的50日移動均線切入位為26.26美元,200日移動均線切入位為24.96美元。該公司的債務權益比為0.28,流動比率為2.24,速動比率為1.89。Alkermes plc股價跌至21.75美元的12個月低點,以及32.79美元的12個月高點。該公司市值為47.1億美元,本益比為-36.78,貝塔係數為0.57。
艾爾建(納斯達克代碼:ALKS-GET Rating)最近一次發佈季度收益數據是在11月2日星期三。該公司公佈本季度每股收益(0.14美元),低於普遍預期的(0.13美元)和(0.01美元)。Alkermes的淨利潤率為負11.41%,股本回報率為負1.10%。該公司本季度營收為2.5236億美元,高於分析師預期的2.7145億美元。去年同期,該業務實現每股收益0.02美元。與去年同期相比,該公司本季度的收入下降了14.2%。研究分析師預計,alkermes plc本財年的每股收益將為0.29歐元。華爾街分析師也加入進來
ALKS一直是幾份分析師報告的主題。美國銀行在1月8日週日的一份報告中將Alkermes的目標價從27.00美元上調至28.00美元。派珀·桑德勒在11月3日週四的一份研究報告中將Alkermes的評級從中性上調至增持,並將該股目標價從26.00美元上調至30.00美元。在11月2日週三發佈的一份研究報告中,StockNews.com將Alkermes的評級從“強力買入”下調至“買入”。摩根大通將Alkermes的目標價從33.00美元下調至29.00美元,並在12月6日(星期二)的一份研究報告中將該股的評級定為“中性”。最後,瑞穗在11月22日週二的一份研究報告中將Alkermes的目標價從34.00美元上調至36.00美元,並給予該股“買入”評級。四名研究分析師對該股的評級為持有,四名分析師對該股的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為“中等買入”,共識目標價為29.89美元。
關於阿爾克姆斯
(獲取評級)
Alkermes Plc是一家全球生物製藥公司。它從事開發、製造和商業化藥物的業務,旨在解決主要治療領域患者未得到滿足的醫療需求。其專有產品包括Aristada、Aristada Initio、LYBALVI和VIVITROL。
推薦故事
- 免費獲取StockNews.com關於Alkermes的研究報告(ALKS)
- T-Mobile在對投資者最重要的領域提供服務
- 埃克森美孚可能很快創下新高
- Costco繼續在正確的時間成為正確的股票
- 佩洛頓可能會獎勵交易員,需要長期紀律
- Bed Bath&Beyond正在繞著排水溝走
想看看還有哪些對沖基金持有ALKS嗎?訪問HoldingsChannel.com獲取Alkermes plc(納斯達克代碼:ALKS-GET Rating)的最新13F備案檔案和內幕交易資訊。
接受Alkermes Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alkermes和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧